News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

Epigenomics AG: Resignation of Supervisory Board Chairman Heino von Prondzynski

EQS-News: Epigenomics AG / Key word(s): PersonnelEpigenomics AG: Resignation of Supervisory Board Chairman Heino von Prondzynski 27.01.2023 / 18:08 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics AG: Resignation of Supervisory Board Chairman Heino von Prondzynski Berlin (Germany), January 27, 2023 -The Chairman of the Supervisory Board of Epigenomics AG (Frankfurt […]

Read more

​​​​​​​Pareto Securities AS publishes buy recommendation for Epigenomics AG share

EQS-News: Epigenomics AG / Key word(s): Research Update/Study results​​​​​​​Pareto Securities AS publishes buy recommendation for Epigenomics AG share 23.12.2022 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Pareto Securities AS publishes buy recommendation for Epigenomics AG share Berlin (Germany), December 23, 2022 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: […]

Read more

Epigenomics Releases Performance Data on Next Generation Test

EQS-News: Epigenomics AG / Key word(s): Study results/MiscellaneousEpigenomics Releases Performance Data on Next Generation Test 14.12.2022 / 05:23 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics Releases Performance Data on Next Generation Test Epigenomics’ Next Generation test demonstrates 84% sensitivity in pre-clinical testing. Performance exceeds on-market standard of FIT testing for […]

Read more

Epigenomics Licenses Protein Biomarker Technology for Blood-based Colorectal Cancer Test

EQS-News: Epigenomics AG / Key word(s): Alliance/MiscellaneousEpigenomics Licenses Protein Biomarker Technology for Blood-based Colorectal Cancer Test 14.12.2022 / 05:16 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics Licenses Protein Biomarker Technology for Blood-based Colorectal Cancer Test Combined technologies have the potential to create a high-performance, cost-effective, blood-based CRC testing solution Berlin […]

Read more

​​​​​​​Epigenomics AG reports financial results for the first nine months 2022

EQS-News: Epigenomics AG / Key word(s): 9 Month figures/Quarter Results​​​​​​​Epigenomics AG reports financial results for the first nine months 2022 09.11.2022 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics AG reports financial results for the first nine months 2022   Berlin (Germany) and San Diego, CA (U.S.A.), November 9, […]

Read more

Epigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test

EQS-News: Epigenomics AG / Key word(s): StudyEpigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test 19.09.2022 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer test First subject has been enrolled in the Company’s CRC-DRAW trial Data […]

Read more